SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins
ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
ARS Pharmaceuticals Provides Commercial and Financial Updates
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals Q1 Earnings Call Highlights
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
Got $300? 2 Biotech Stocks to Buy and Hold Forever
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to
Campbell & CO Investment Adviser LLC Takes Position in ARS Pharmaceuticals, Inc. $SPRY
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
FAS Wealth Partners Inc. Buys 51,460 Shares of ARS Pharmaceuticals, Inc. $SPRY
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of “Moderate Buy” by Brokerages
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
53,341 Shares in ARS Pharmaceuticals, Inc. $SPRY Purchased by Permanent Capital Management LP
Ardsley Advisory Partners LP Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Xeris Biopharma (NASDAQ:XERS)
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of “Moderate Buy” from Analysts
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
ARS Pharmaceuticals: A Significant Upside Is Expected From neffy